Cardlytics Inc (NASDAQ:CDLX)’s stock price shot up 5.5% during mid-day trading on Friday . The company traded as high as $98.50 and last traded at $98.16, 437,299 shares traded hands during trading. A decline of 10% from the average session volume of 485,600 shares. The stock had previously closed at $93.07.

A number of research firms recently issued reports on CDLX. Craig Hallum boosted their price objective on Cardlytics from $75.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, January 14th. Bank of America reiterated an “average” rating and set a $100.00 price objective on shares of Cardlytics in a research note on Tuesday, January 14th. JPMorgan Chase & Co. lowered Cardlytics from an “overweight” rating to a “neutral” rating and set a $58.00 price objective on the stock. in a research note on Thursday, November 14th. They noted that the move was a valuation call. Raymond James lowered Cardlytics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 15th. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded Cardlytics from a “hold” rating to a “buy” rating and set a $93.00 price objective on the stock in a research note on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $66.43.

The firm has a market capitalization of $2.17 billion, a P/E ratio of -68.64 and a beta of 1.65. The business has a 50 day simple moving average of $79.33 and a two-hundred day simple moving average of $51.29.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Tuesday, November 12th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.31. The business had revenue of $56.42 million for the quarter, compared to analyst estimates of $50.02 million. Cardlytics had a negative return on equity of 44.53% and a negative net margin of 17.01%. The company’s quarterly revenue was up 63.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.15) EPS. On average, analysts predict that Cardlytics Inc will post -0.9 EPS for the current year.

In other Cardlytics news, Director Bryce Youngren sold 61,689 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $55.48, for a total value of $3,422,505.72. Following the transaction, the director now directly owns 8,484 shares in the company, valued at approximately $470,692.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kirk Somers sold 1,500 shares of the company’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $58.70, for a total value of $88,050.00. The disclosure for this sale can be found here. Insiders sold a total of 597,049 shares of company stock worth $40,943,861 over the last 90 days. Corporate insiders own 21.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Schonfeld Strategic Advisors LLC bought a new position in Cardlytics in the 4th quarter worth about $543,000. Bank of America Corp DE increased its stake in Cardlytics by 17.6% in the 4th quarter. Bank of America Corp DE now owns 384,977 shares of the company’s stock worth $24,200,000 after acquiring an additional 57,595 shares during the last quarter. UBS Asset Management Americas Inc. bought a new position in Cardlytics in the 4th quarter worth about $1,095,000. Bank of New York Mellon Corp increased its stake in Cardlytics by 351.1% in the 4th quarter. Bank of New York Mellon Corp now owns 440,251 shares of the company’s stock worth $27,673,000 after acquiring an additional 342,660 shares during the last quarter. Finally, CAS Investment Partners LLC increased its stake in Cardlytics by 21.7% in the 4th quarter. CAS Investment Partners LLC now owns 2,821,710 shares of the company’s stock worth $177,373,000 after acquiring an additional 502,299 shares during the last quarter. Institutional investors and hedge funds own 93.65% of the company’s stock.

About Cardlytics (NASDAQ:CDLX)

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Recommended Story: What Are Cryptocurrencies?

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.